Monkeypox Market Size, Epidemiology and Market Forecast – 2032

Posted 2024-10-25 10:41:12

133

Monkeypox is a viral zoonotic disease caused by the monkeypox virus, related to the variola virus that causes smallpox. Monkeypox, primarily endemic in parts of Central and West Africa, has seen cases emerge globally, leading to renewed focus on treatment and prevention. Symptoms include fever, rash, and swollen lymph nodes, and while often less severe than smallpox, complications can be serious, particularly in immunocompromised individuals. Human-to-human transmission, especially in areas outside of Africa, has amplified the need for effective therapeutics and vaccines.

Monkeypox Market Insight

The monkeypox market has expanded significantly following the 2022 outbreak, with demand rising for antiviral treatments, diagnostics, and vaccines. Vaccination remains a key preventive approach, with several vaccines, such as JYNNEOS and ACAM2000, repurposed from smallpox to provide protection against monkeypox. Demand for antiviral medications like Tecovirimat (TPOXX) has increased due to its efficacy in treating orthopoxvirus infections. As governments and organizations allocate resources to preparedness, the market is expected to grow, driven by advancements in diagnostic tools and expanded manufacturing of vaccines and treatments.

Key Monkeypox Companies In The Market Landscape:

The key Monkeypox companies in the market include - Bavarian Nordic A/S, SIGA Technologies, Inc., Emergent BioSolutions Inc., Johnson & Johnson, Novavax, Inc., GeoVax Labs, Inc., Chimerix, Inc., BioCryst Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation, Inovio Pharmaceuticals, Inc., and others.

Monkeypox Epidemiology Overview

Monkeypox cases have surged in non-endemic regions, with confirmed cases reported in North America, Europe, and Asia. The Monkeypox epidemiology reflects an evolving transmission pattern, which has raised concerns of monkeypox becoming more prevalent globally. Countries have increased surveillance and case reporting, resulting in comprehensive databases that provide insight into monkeypox’s spread. High-risk populations, particularly those in close-contact communities, are primary targets for preventive care and treatment, underscoring the demand for accessible healthcare solutions.

Monkeypox Market Forecast – 2032

The monkeypox market size is anticipated to see steady growth through 2032, with projections indicating an increase in funding for vaccine production, antiviral development, and rapid diagnostic tools. The market’s expansion will be supported by continued R&D investment, awareness campaigns, and health policy measures, particularly in non-endemic regions. Major companies are expected to bolster production of vaccines and therapies, with additional pipeline developments for targeted treatments.

Conclusion:

Increased understanding and preparedness for monkeypox will drive the market over the next decade. The forecast period through 2032 promises growth, innovation, and enhanced access to essential tools to combat monkeypox, strengthening global health resilience.